Company Update - Phase 1 Study Independent Review

<p class="typography-body-regular"><u><strong>Highlights</strong></u></p>

<ul>

<li class="typography-body-regular"><strong>Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance Imaging (MRI).</strong></li>

<li class="typography-body-regular"><strong>Company now prioritising the development of its pipeline of tumour targeting MagSense® imaging agents for use with widely available commercial MRI systems as a faster path to patients and the market.</strong></li>

</ul>